Samlyn Capital’s Moderna MRNA Stock Holding History

Samlyn Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-74,000	Closed	-$7.73M	–	187
2020 Q4	$7.73M	Buy	+74,000	New	+$7.49M	0.11%	96

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Samlyn Capital's MRNA Position: Q1 2019 in Review

Samlyn Capital sold out of Moderna (MRNA) in Q1 2019, closing a stake of 325,000 shares — an estimated $4.96M sold.

Samlyn Capital first reported a position in MRNA in Q4 2018 and held it in 1 quarter. The position peaked at $4.96M in Q4 2018. 106 funds tracked by Wall St. Rank hold MRNA as of Q1 2019.

Samlyn Capital reported no remaining Moderna position as of Q1 2019 after selling out during the quarter.
Samlyn Capital sold 325,000 Moderna shares in Q1 2019, an estimated $4.96M.
Samlyn Capital first reported a position in Moderna in Q4 2018 and held it in 1 quarter.
Samlyn Capital's Moderna position peaked at $4.96M in Q4 2018.
106 funds tracked by Wall St. Rank held Moderna as of Q1 2019.

Based on Samlyn Capital's 13F filing for Q1 2019, filed 15 May 2019.